By: TN Media News Dubai, UAE
A Landmark Event in Hematology:
The 6th Middle East, Africa, and Russia Hematology Summit (MASH) was successfully held at Intercontinental Festival City, Dubai, with the support of AbbVie, a global biopharmaceutical leader. The annual event has become a vital platform for regional collaboration in hematology, bringing together over 25 experts and speakers from across the Middle East, Africa, Russia, Canada, and the United States.
This year’s edition built on the success of previous years, fostering deeper engagement among medical professionals and researchers in the field.
Workshops and Clinical Experience in Focus:
The 2025 summit placed strong emphasis on clinical practice and knowledge sharing. A full day of the program was dedicated to interactive workshops for hematologists and clinical pharmacists. These sessions focused on managing complex blood disorders and real-world patient cases.
An international expert also led a specialized workshop on the role of artificial intelligence and precision medicine in treating hematological diseases.
Expert Praise for Advancements and Participation:
Dr. Ayman Al-Hijazi, Consultant Hematologist at King Abdulaziz Medical City, Riyadh, commended the summit’s high-level attendance and scientific content. He highlighted discussions on new diagnostic tools and advanced treatments for AML, CLL, and lymphoma.
He also praised presentations that showcased progress in managing refractory multiple myeloma and integrating AI in personalized oncology treatment.
Comprehensive Coverage of Blood Disorders:
Dr. Abdulwahab Al-Babtain, Consultant Hematologist at King Faisal Specialist Hospital, noted the summit’s wide-ranging scientific value. Topics included:
-
Lymphoma and leukemia case management
-
Sequencing treatments for chronic lymphocytic leukemia
-
Complication management in blood cancers
-
The role of genetic testing in AML treatment
Dr. Abdulwahab stressed that new medications, guided by the latest research, are helping reduce patient suffering. He emphasized the importance of choosing personalized treatment plans, tailored to individual cases and aligned with international guidelines.
AbbVie’s Vision: Education and Innovation:
Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, reiterated the company’s commitment to advancing medical research and professional development. He stated that summits like MASH support AbbVie’s goal to deliver transformative care, in line with Saudi Arabia’s Vision 2030.
This edition of the summit demonstrated how early detection, AI-driven diagnostics, and innovative therapies can close clinical gaps and improve patient outcomes.
Looking Ahead:
The 6th MASH Summit once again served as a key forum for collaboration, learning, and discovery in hematology. With its combination of global expertise, hands-on workshops, and forward-looking discussions, the summit is expected to continue driving transformational progress in the diagnosis and treatment of blood diseases throughout the region.
#MASH2025 | #DubaiHematologySummit | #AbbVie | #AIinHealthcare | #BloodDisorderTreatment | #Vision2030 | #PrecisionMedicine
